Advocates Press Auchincloss to Back Alpha-Gal Labeling Bill for 500,000 Americans
Updated
Updated · The Boston Globe · Jul 18
Advocates Press Auchincloss to Back Alpha-Gal Labeling Bill for 500,000 Americans
1 articles · Updated · The Boston Globe · Jul 18
Summary
April meetings with Rep. Jake Auchincloss’s office centered on a House bill that would classify alpha-gal as a major food allergen, after patients said hidden animal-derived ingredients in food and medicines can trigger severe reactions.
CDC estimates nearly 500,000 Americans have alpha-gal syndrome, and advocates say clearer labeling is urgent because studies show 75% of patients experience anaphylaxis and 74% of the 100 most prescribed drugs may contain animal-based ingredients.
The push extends to a second House bill requiring prescription-drug makers to label major allergens, closing a gap in federal rules that already cover dietary supplements but not prescription medications.
Cases are rising as lone star ticks expand—the allergy increased fivefold on Martha’s Vineyard from 2023 to 2025—and Massachusetts began mandatory case reporting in April, though researchers warn NIH funding cuts could slow answers on the condition.
Is the Alpha-gal allergy, spread by climate-driven tick expansion, a preview of future environmental epidemics?
As a tick-borne allergy skyrockets across America, why is vital medical research funding facing cuts?
Could hidden animal products in your medicine or makeup trigger a severe allergy from a single tick bite?
450,000 Americans at Risk: The Legislative and Public Health Battle for Alpha-gal Allergen Labeling
Overview
Congress is urgently advancing bipartisan legislation to address Alpha-gal Syndrome (AGS) by requiring clear labeling of alpha-gal on packaged foods. This push is fueled by rising public health concerns and personal experiences of lawmakers affected by AGS. The proposed H.R. 1178 bill aims to classify alpha-gal as a major food allergen, making its identification on labels mandatory. Clear labeling is seen as a critical step for individuals managing AGS, helping them avoid severe allergic reactions. The legislative effort reflects both the growing prevalence of AGS and the need for greater transparency to protect public health.